AI-based drug development
-
Genesis Therapeutics Rakes In $200M For AI-Powered Drug Discovery
Genesis Therapeutics recently joined the growing list of AI-powered drug discovery startups receiving venture funding this year. The company closed a $200 million Series B financing round, taking its total funding to date to more than $280 million.
-
MedCity Influencers, Devices & Diagnostics, BioPharma
Digital as the Differentiator for Biopharma and Medtech
Pharma players, now more than ever, need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Artificial Intelligence, BioPharma
AI offers promise but faces barriers in drug development
Inertia is a barrier as is the traditional split between the clinical and the data-driven spheres of drug development. While smaller firms have an edge in bridging the gap, big pharma will eventually get there, said panelists at the INVEST conference session.
-
Startups, Artificial Intelligence, BioPharma
Personalized cancer treatment startup Notable Labs nabs $40M Series B
Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company’s technology and growth of its commercial use cases.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
